Announcement and Pricing Details
Taysha Gene Therapies (NASDAQ:TSHA) disclosed that it has priced an underwritten public offering consisting of 32,500,001 shares of common stock at $6.00 per share. In addition, the company priced pre‑funded warrants that allow the purchase of 833,333 shares at $5.999 per warrant, both prices stated before underwriting discounts, commissions, and other offering expenses.
Expected Proceeds and Underwriter Option
The firm expects gross proceeds of approximately $200.0 million from the offering, also stated before deducting underwriting discounts, commissions, and other related expenses. Underwriters have been granted a 30‑day option to purchase up to an additional 5,000,000 shares at the same public offering price, less the customary discounts and commissions.
Closing Timeline
The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.
Book‑Running Managers
Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book‑running managers for the transaction, while Baird is serving as the lead manager.
Market Reaction
Following the pricing announcement, Taysha Gene Therapies shares fell roughly 13% in pre‑market trading on Thursday.